Sm08502-onc-01
Webb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and … Webb6 jan. 2024 · Mel J. Yeates. SAN DIEGO—In late 2024, Samumed, LLC noted the publication of data demonstrating a novel mechanism of action for SM08502 in preclinical …
Sm08502-onc-01
Did you know?
WebbORG STUDY ID : SM08502-ONC-01 NCT ID : NCT03355066 Conditions Solid Tumor, Adult Interventions Purpose This study is an open-label, multi-center, dose-escalation, dose … WebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology at Biosplice …
WebbThe study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). … Webb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK …
http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs Webb28 nov. 2024 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors The safety and scientific validity of …
Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC …
solid dark mango wood furniture houstonWebbLogin. Nctid: NCT03355066 Payload: solid dick from iron manWebb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic’s comprehensive platform to characterize drug activity and patient response in Biosplice’s SM08502-ONC … solid deck hardwood dollyWebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically … solid deals todayWebbApply to this Phase 1 clinical trial treating Non-small Cell Lung Cancer, Colorectal Carcinoma (CRC), Castration-resistant Prostate Cancer. Get access to cutting edge … solid dairy product crosswordWebb1 sep. 2024 · Characterization of SM08502, a small-molecule CLK inhibitor of Wnt activity. (A) SM08502 inhibited the activity of CLK kinases. CLK2, CLK3, and CDK1 kinase IC 50 s … solid cushion wheel with pin endsWebb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology … solid dark mango wood furniture